Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -0.43% 116.00 114.00 118.00 116.50 116.00 116.50 67,612 09:36:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 66

Reneuron Share Discussion Threads

Showing 7801 to 7821 of 8325 messages
Chat Pages: Latest  321  320  319  318  317  316  315  314  313  312  311  310  Older
DateSubjectAuthorDiscuss
24/2/2020
07:30
I'm curious how the non medicated eye also shows some (smaller) progress over time. I would expect it to deteriorate over a 12m period but I'd does not. Is that placebo effect? I would not expect placebo would allow you to read more lines. Thoughts?
cottonpickers
24/2/2020
07:21
Positive news, let's see what the market make of it
ayl30
24/2/2020
07:08
The news we have all been waiting for!
bonzo
23/2/2020
07:57
Do not click that link from petershares1- same spam link as yesterday. There is no Times article..
dplewis1
22/2/2020
22:06
hxxps://youtu.be/i2xK3Ls0jFU
peteark
22/2/2020
12:07
I was thinking about a takeover bid by someone in the industry. A third of the company has been available for weeks, if not months. Even now, the very recent buyer of 16% would, I'm sure, be very happy to take a fast profit.
dickbush
19/2/2020
17:31
I have to wonder why-if RENE has such great prospects-no one seems to want to buy it on the cheap.
dickbush
18/2/2020
09:57
So that 👎🏽 Was you?🤣
rayrac
18/2/2020
08:12
Rayrac, it's a statement of record and a material fact so they can hardly suppress it..
bonzo
18/2/2020
07:40
Novartis!?
rayrac
17/2/2020
13:32
Someuwin!👎🏽🤣
rayrac
17/2/2020
12:24
I don’t appreciate news like this from rene, that has the appearance of ramping. Put up, or shut up! As said, it’s old stuff.
rayrac
17/2/2020
09:15
And down we go again.... same old.
investordave
17/2/2020
07:56
RENE ReNeuron says positive clinical data from Phase 2a trial of its CTX stem cell therapy candidate published in peer-reviewed journal HTTP://twitter.com/entropick/status/1229313536347836416
entropick
17/2/2020
07:33
This is only news of formal publication, the results are not new. Interesting to see if it affects the price.
bonzo
17/2/2020
07:21
"We are delighted to see the positive results of the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability published in this highly regarded peer-reviewed journal." I am sure the patients who improved were even more delighted! Great news for them and hope that RENE can help many more in future! Great news.
lauders
17/2/2020
07:18
That was a smiley face not a question mark!
ayl30
17/2/2020
07:15
ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke. Data from the study were originally presented by Professor Keith Muir at the American Heart Association International Stroke Conference 2018 (ISC 2018) in January 2018, having been announced by the Company in October 2017. Data from the PISCES II clinical trial have been published online in the Journal of Neurology, Neurosurgery, and Psychiatry in a paper titled Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2)", Keith Muir et al. hxxp://jnnp.bmj.com/cgi/content/full/jnnp-2019-322515 PISCES II was a single arm, open-label study in patients living with significant disability resulting from ischaemic stroke. A total of 23 stable stroke patients with moderate to severe disability were treated with a single dose of 20 million CTX cells a median of seven months post-stroke. Clinically meaningful improvements in disability scales were measured out to 12 months post-implantation. The greatest improvements on the Modified Rankin Scale (mRS), a measure of disability and dependence, were seen in a pre-specified group of fourteen subjects with residual movement of the affected arm (NIHSS Upper Limb <4). Of these patients, 38.5% were responders (at least a one-point improvement on mRS) at six months post treatment and 50% were responders at twelve months post treatment on this measure. A one-point improvement in mRS is proven to be clinically meaningful for patients, both in terms of quality of life and healthcare resources needed to care for them. For example, improving from mRS 3 to 2 means that a person with a stroke regains their ability to live independently; perhaps returning home from a care facility, or enabling a spouse or carer to return to work. The ongoing PISCES III study is a larger, randomised, placebo controlled clinical trial designed to show a significant difference in the proportion of patients with at least a one-point improvement on mRS in a group receiving CTX stem cells compared to a group receiving a sham-surgery procedure. Olav Hellebø, Chief Executive Officer of ReNeuron, commented: "We are delighted to see the positive results of the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability published in this highly regarded peer-reviewed journal."
peteark
12/2/2020
12:45
Let's hope so. No doubt though they'll still be some numpties selling up for the price of a weekly shop.
investordave
12/2/2020
10:12
Good backing too! More than can be said for a share like Opti! :)
rayrac
12/2/2020
09:29
Yes, overhang cleared so should rise from here.
someuwin
Chat Pages: Latest  321  320  319  318  317  316  315  314  313  312  311  310  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210614 09:57:40